Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

Despite treatment advances that have improved patient survival, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs), multiple myeloma (MM) remains incurable.1,2 Most patients ultimately relapse or become refractory to standard drug classes.3,4 Triple-class exposed patients with relapsed/refractory MM (RRMM) have particularly aggressive disease and a poor prognosis.5 This may, in part, be due to the increasing genetic complexity and more drug-resistant mutations that occur with each new line of therapy (LOT), particularly for patients with high-risk cytogenetics.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research